Molecular Tumor Boards in Clinical Practice

Area of Science:

• Oncology
• Genomics
• Clinical Pathology

Background:

• Next-generation sequencing (NGS) offers advanced molecular profiling for cancer patients.
• Integrating NGS into clinical practice necessitates structured multidisciplinary approaches.
• Molecular Tumor Boards (MTBs) are emerging as essential platforms for this integration.

Purpose of the Study:

• To systematically review and define the critical components and operational aspects of Molecular Tumor Boards (MTBs).
• To provide a framework for establishing and optimizing MTBs for clinical NGS implementation.
• To address key considerations for effective MTB function in precision oncology.

Main Methods:

• Systematic literature review of studies related to Molecular Tumor Boards.
• Analysis of key MTB elements including aims, composition, tumor types, molecular analyses, and actionability classification.
• Evaluation of operational factors such as turnaround time and cost management.

Main Results:

• MTBs require defined aims, appropriate multidisciplinary composition, and clear criteria for tumor selection.
• Standardized molecular analyses and robust methods for classifying treatment actionability are vital.
• Efficient turnaround times and effective cost management are critical for clinical utility.

Conclusions:

• Molecular Tumor Boards are indispensable for translating NGS findings into actionable clinical decisions.
• Successful MTB implementation requires careful planning regarding scope, analysis, and operational logistics.
• Optimized MTBs facilitate precision medicine by guiding targeted therapy selection based on comprehensive genomic profiling.